

## **REMARKS**

The present invention relates to a method of treatment or prophylaxis of inflammatory bowel disease (IBD) comprising administration of a therapeutically effective amount of an inhibitor of CSF-1 activity, wherein the inhibitor is an anti-CSF-1 antibody or CSF-1 binding fragment of an anti-CSF-1 antibody.

The withdrawal of prior rejections and objections as stated in paragraphs 3, 4, and 6 of the Office Action is noted with appreciation.

### **Rejection Under 35 USC §112, second paragraph**

With regard to paragraph 5 of the Office Action in which claims 15-19 were rejected for indefiniteness, claims 15 and 17 have been amended to replace “epitope-binding” with “CSF-1 bonding,” and language relating to derivatives has been deleted. It is respectfully submitted that these amendments are sufficient to overcome the rejection under 35 USC §112, second paragraph.

### **Rejection Under 35 USC §102**

Claims 12, 15-19, and 21-22 stand rejected under 35 USC 102(e) as being anticipated by Bedian et al. US 2005/0059113 (hereinafter “Bedian”). Without acquiescing in this ground of rejection, applicants submit herewith the “Declaration of Alastair David G. Lawson, Diane Marshall and Timothy Bourne Under 37 C.F.R. §1.131,” with Exhibit 1. Exhibit 1 is redacted pages of the laboratory notebook in which was recorded the laboratory work reported in the patent application. In particular, work reported in the patent at Figures 1-6 corresponds to the graphs at notebook page numbers 2, 3, 4, 22, and 26 of the Exhibit. Other pages of the Exhibit include in tabular form the data from which these figures were generated. As stated in the Declaration at paragraph 6, each of these pages is dated in the upper right-hand corner with a date prior to the September 10, 2003 priority date of Bedian. The date in the upper right hand corner of the page indicates the date on which the experiment was conducted (see Declaration at paragraph 5).

This Declaration and Exhibit evidence the fact that the claimed invention was conceived and reduced to practice by the inventors prior to the September 10, 2003 priority date of Bedian. Accordingly, the presently claimed invention was not described in an application for patent by another filed before the invention by these applicants for patent under 35 USC 102(c). It is therefore requested that this ground of rejection be withdrawn.

Submitted herewith is a Request to Add an Inventor, a Declaration of all the inventors, a Statement by the added inventor pursuant to 37 CFR 1.48(a)(2), and a Consent of Assignee to Add Inventor Pursuant to 37 CFR 1.48(a)(5). Appropriate assignments are being submitted for recordation concurrently with this filing.

Finally, Applicants note a typographical error in the title of the specification as entered in the Office's records. Applicants respectfully request correction of the title to reflect amendments filed on April 21, 2009 as follows:

Methods for the Treatment of Inflammatory Bowel Disease By Administration of an **Inhibitor** of CSF-1 Activity

### **CONCLUSION**

As all grounds of rejection have been overcome, a Notice of Allowance is requested. The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-3362 if the Examiner believes that this would expedite prosecution of this application.

Respectfully submitted,

Date: October 13, 2009

By: /Sandra B. Weiss/

Sandra B. Weiss  
Reg. No. 30,814  
McDonnell Bochen Hulbert & Berghoff LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
(312) 913-3362